NSRX Nasus Pharma Ltd.: Bathi resik saben saham sajrone 12 wulan pungkasan

The market price visualization of EPS (TTM) for Nasus Pharma Ltd (NSRX) demonstrates a figure of 0.00. Business stability relies on regulatory approvals and the success of tests for treatments against viral infections and overdoses. B2B contracts and the implementation of unique nasal drug delivery methods drive positive momentum. Despite its narrow specialization in emergency airway protection, Nasus Pharma Ltd (NSRX) successfully monetizes its developments through retail pharmacies.
Rincian metrik keuangan lan pasar Nasus Pharma Ltd (NSRX)

This indicator measures the net profit per share dynamics over the last twelve months, allowing investors to filter out market noise and assess the actual efficiency of capital generation. By analyzing the current EPS YoY TTM growth rate, one can compare market volatility with the results of the Nasus Pharma (NSRX) pharmaceutical team's efforts to monetize intellectual property and implement its technological platforms.